In regards to surgery it is recommended to perform total omentectomy since subclinic metastasis have been documented in 10 - 30 % of all cases , and systematic limphadenectomy , necessary to be able to obtain an adequate surgical staging .
Minimal invasion surgery is not a recommended procedure for the treatment of advanced ovarian cancer .
Radiotherapy can be used to palliate symptoms .
In the present , there is not a st and ardized screening method .
Diagnosis in early stages means a better survival .
Radiotherapy can be indicated to palliate symptoms
INTRODUCTION Ovarian cancer ( OC ) is the third most common gynecologic malignancy worldwide .
Most of cases it is of epithelial origin .
At the present time there is not a st and ardized screening method , which makes difficult the early diagnosis .
The 5-year survival is 90 % for early stages , however most cases present at advanced stages , which have a 5-year survival of only 5 - 20 % .
GICOM collaborative group , under the auspice of different institutions , have made the following consensus in order to make recommendations for the diagnosis and management regarding to this neoplasia .
Until now , laparoscopy for diagnostic-staging surgery is not well known as a recommended method .
In advanced stages , primary cytoreduction is recommended as initial treatment .
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
PURPOSE The management of recurrent ovarian cancer remains controversial . Single-agent topotecan is an established treatment option , and preliminary evidence suggests improved tumor control by combining topotecan with etoposide or gemcitabine . PATIENTS AND METHODS Women with relapsed ovarian cancer after primary surgery and platinum-based chemotherapy were r and omly assigned to topotecan monotherapy 1.25 mg/m(2)/d , topotecan 1.0 mg/m(2 ) plus oral etoposide 50 mg/d , or topotecan 0.5 mg/m(2)/d plus gemcitabine 800 mg/m(2 ) on day 1 and 600 mg/m(2 ) on day 8 every 3 weeks . Patients were stratified for platinum-refractory and platinum-sensitive disease according to a recurrence-free interval of less or more than 12 months , respectively . The primary end point was overall survival . Secondary end points included progression-free survival , objective response rates , toxicity , and quality of life ( as measured by the European Organisation for Research and Treatment of Cancer [ EORTC ] 30-item Quality -of-Life Question naire ) . RESULTS The trial enrolled 502 patients with a mean age of 60.5 years ( + /- 10.2 years ) , 208 of whom were platinum resistant .  Median overall survival was 17.2 months ( 95 % CI , 13.5 to 21.9 months ) with topotecan , 17.8 months ( 95 % CI , 13.7 to 20.0 months ) with topotecan plus etoposide ( log-rank P = .7647 ) , and 15.2 months ( 95 % CI , 11.3 to 20.9 months ) with topotecan plus gemcitabine ( log-rank P = .2344 ) . Platinum-sensitive patients lived significantly longer than platinum-refractory patients ( 21.9 v 10.6 months ) . The median progression-free survival was 7.0 , 7.8 , and 6.3 months , respectively . Objective response rates were 27.8 % , 36.1 % , and 31.6 % , respectively . Patients under combined treatment were at higher risk of severe thrombocytopenia . CONCLUSION Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer
In regards to surgery it is recommended to perform total omentectomy since subclinic metastasis have been documented in 10 - 30 % of all cases , and systematic limphadenectomy , necessary to be able to obtain an adequate surgical staging .
Minimal invasion surgery is not a recommended procedure for the treatment of advanced ovarian cancer .
Radiotherapy can be used to palliate symptoms .
In the present , there is not a st and ardized screening method .
Diagnosis in early stages means a better survival .
Radiotherapy can be indicated to palliate symptoms
INTRODUCTION Ovarian cancer ( OC ) is the third most common gynecologic malignancy worldwide .
Most of cases it is of epithelial origin .
At the present time there is not a st and ardized screening method , which makes difficult the early diagnosis .
The 5-year survival is 90 % for early stages , however most cases present at advanced stages , which have a 5-year survival of only 5 - 20 % .
GICOM collaborative group , under the auspice of different institutions , have made the following consensus in order to make recommendations for the diagnosis and management regarding to this neoplasia .
Until now , laparoscopy for diagnostic-staging surgery is not well known as a recommended method .
In advanced stages , primary cytoreduction is recommended as initial treatment .